Lakeshore biopharma granted phase iii clinical trial approval to explore simplified regimens for ysja rabies vaccine

Gaithersburg, md. , oct. 25, 2024 /prnewswire/ -- lakeshore biopharma co., ltd (nasdaq: lsb) ("lakeshore biopharma" or the "company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has been granted approval for a phase iii clinical trial (the "trial") by the national medical products administration (nmpa) in china to explore the immunogenicity and safety of a simplified four-dose regimen for its ysja rabies vaccine which is the first generation of the company's rabies vaccine and has sold more than 100m doses since its market approval.
LSB Ratings Summary
LSB Quant Ranking